Full Press Release Details
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis.
ARGX
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
Key Takeaway: argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
Price reaction · baseline $323.1 (2022-05-27 close) · hit after-hours · 1 other ARGX headline(s) in the window, move may be shared
day 0 close · peak
-4.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis